MLND Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2021 @ 06:00):

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States...

Stats
Dagens volum	1.91M
Gjennomsnittsvolum	140 975
Markedsverdi	11.15M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0940 (8.87%)

Insider Trading

Date	Person	Action	Amount	type
2020-06-22	Nuechterlein Carole	Buy	12 000	Stock Option (right to buy)
2020-06-22	Howe John P Md	Buy	12 000	Stock Option (right to buy)
2020-06-22	Gallagher Carol Giltner	Buy	12 000	Stock Option (right to buy)
2020-06-22	Nichol Geoffrey	Buy	12 000	Stock Option (right to buy)
2020-06-22	Hindman James M.	Buy	12 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 34 transactions
Buy: 816 539 \| Sell: 0

Volum Korrelasjon

Lang: -0.37 (neutral)

Kort: 0.79 (moderate)

Signal:(35.927) Neutral

Millendo Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Millendo Therapeutics Inc Korrelasjon - Valuta/Råvare

0.64
( weak )

-0.17
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.69
( moderate negative )

-0.61
( weak negative )

Millendo Therapeutics Inc Økonomi

Annual	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-28.95

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-28.95

FY	2019
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-48.75

FY	2018
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-263.70

Financial Reports:

No articles found.

Millendo Therapeutics Inc

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.